Best International Stocks To Own For 2015

Best International Stocks To Own For 2015: ICON plc(ICLR)

ICON Public Limited Company, a contract research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, the United States, and rest of Europe. It specializes in strategic development, management, and analysis of programs that support various stages of clinical development process from compound selection to Phase I to IV clinical studies. The company?s clinical research services include investigator recruitment, study monitoring and data collection, case report form preparation, patient safety monitoring, clinical data management, interactive voice response, electronic patient reported outcomes, medical reporting, patient registries, outcomes research, and health economics. Its clinical research services also comprise marker access and commercialization services, strategic analysis and data operation, clinical pharmacology, bioanalysis, immunoassay development, pharmacokinetic and pharmacodynam ic analysis, study protocol preparation, regulatory consulting, product development planning, strategic consulting, medical imaging, contract staffing, and electronic endpoint adjudication. In addition, the company offers various laboratory services, such as sample analyses, safety testing, microbiology, custom flow cytometry, electronic transmission of test results, and biomarker development. ICON Public Limited Company was founded in 1990 and is headquartered in Dublin, Ireland.

Advisors' Opinion:

• [By Louis Navellier]

  European Stocks to Buy: ICON Public Limited (ICLR)

  ICON Public Limited Company (ICLR) is a contract research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, the United States, and Europe. They provide management, and analysis of programs! that support various stages of clinical development process from compound selection to Phase I to IV clinical studies as well as lab services for companies conducting trials. The company has posted triple digit earnings gains and posted four consecutive positive earnings surprises in the past year. Analysts have been raising their estimates for the Irish company and Portfolio Grader raised the stock to an A last month. The stock is a strong buy at today's price.

source from Top Stocks For 2015:http://www.topstocksblog.com/best-international-stocks-to-own-for-2015-3.html